 vivo model somatic cell gene therapy human severe immunodeficiency Deficiency adenosine deaminase ADA results severe immunodeficiency SCID candidate genetic disorder somatic cell gene therapy Peripheral blood lymphocytes patients ADA- SCID retroviral vector human ADA immunodeficient mice Long-term survival vector-transduced human cells recipient animals Expression vector-derived ADA immune functions presence reconstituted animals human immunoglobulin antigen-specific cells Retroviral vector gene transfer necessary sufficient development specific immune functions vivo therapeutic potential lethal immunodeficiency